A seasoned clinical strategist with over 15 years of experience in his field, Robert Hindes, MD, serves as the chief medical officer of Cambridge, Massachusetts-based Trek Therapeutics, PBC. As the former vice president of Clinical Trials at Pharmasset, Inc., he oversaw all phase II-III clinical trials, all involving the nucleotide prodrug sofosbuvir for the treatment of hepatitis C virus (HCV) infection. After a transitional role as the vice president of Clinical Development for Gilead Sciences, Inc., Robert Hindes, MD, cofounded Trek Therapeutics with a primary focus on developing low cost drugs for high medical need patients with poor access to life-saving drugs.
HCV affects the liver and can result in liver failure and other serious symptoms. Although there is a cure, at approximately $1,000 per pill and up to $84,000 for the full course of treatment, it remains cost prohibitive for most. A public benefit corporation, Trek Therapeutics aims to develop affordable but profitable treatment options that can be used in developed and developing countries alike. To date, its portfolio includes two HCV drugs in clinical trial, Faldaprevir (FDV) and TD-6450.
A protease inhibitor acquired from Boehringer Ingelheim, FDV has completed phase III studies, whereas TD-6450 is a NS5A inhibitor that Trek Therapeutics acquired from Theravance Biopharma. The 2 drugs have been combined and are being evaluated in a phase II clinical trial in the US that began in October 2015, and is fully enrolled. Clinical trials in other genotypes have also been initiated in New Zealand. For additional information on Trek Therapeutics’ portfolio, visit www.trektx.com.
HCV affects the liver and can result in liver failure and other serious symptoms. Although there is a cure, at approximately $1,000 per pill and up to $84,000 for the full course of treatment, it remains cost prohibitive for most. A public benefit corporation, Trek Therapeutics aims to develop affordable but profitable treatment options that can be used in developed and developing countries alike. To date, its portfolio includes two HCV drugs in clinical trial, Faldaprevir (FDV) and TD-6450.
A protease inhibitor acquired from Boehringer Ingelheim, FDV has completed phase III studies, whereas TD-6450 is a NS5A inhibitor that Trek Therapeutics acquired from Theravance Biopharma. The 2 drugs have been combined and are being evaluated in a phase II clinical trial in the US that began in October 2015, and is fully enrolled. Clinical trials in other genotypes have also been initiated in New Zealand. For additional information on Trek Therapeutics’ portfolio, visit www.trektx.com.